The FDA on January 27, 2026, approved DARZALEX FASPRO® in combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for Autologous Stem Cell Transplant (ASCT). DARZALEX FASPRO® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
